Contact Us
Drug Search Results
More Filters [+]

Vatalanib

Alternative Names: vatalanib, ptk787, ptk/zk, zk222584, vatalinib, ptk787/zk 222584
Latest Update: 2024-03-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: VEGFR Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Vatalanib

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Colorectal Cancer

Phase 2: Pancreatic Cancer|Neuroendocrine Tumors|Breast Cancer|Mesothelioma|Hemangioblastoma|von Hippel-Lindau Disease|Colorectal Cancer|Vascular Cancer|Preleukemia|Lymphoma, Non-Hodgkin|Diffuse Large B-Cell Lymphoma|Brain Stem Cancer|Wet Macular Degeneration|Non-Small-Cell Lung Cancer|Myeloproliferative Disorders|Myelodysplastic Syndrome|Myelodysplastic-Myeloproliferative Diseases|Sarcoma|Carcinoid Tumor|Gastrointestinal Stromal Tumors|Pleural Cancer|Choroidal Neovascularization|Neuroendocrine Carcinoma|Gastrointestinal Cancer|Melanoma|Malignant Carcinoid Syndrome|Glioblastoma|Islet Cell Carcinoma|Meningioma|Adenocarcinoma|Multiple Myeloma|Prostate Cancer

Phase 1: Carcinoma, Merkel Cell|Endocrine Gland Cancer|Melanoma|Breast Cancer|Kidney Cancer|Healthy Volunteers|Oncology Solid Tumor Unspecified|Fallopian Tube Cancer|Peritoneal Cancer|Cervical Cancer|Ovarian Cancer|Endometrial Cancer|Oncology Unspecified|Brain Stem Cancer|Carcinoid Tumor|Islet Cell Carcinoma|Pheochromocytoma|Medullary Carcinoma|Neuroendocrine Carcinoma|Somatostatinoma|Glucagonoma|Malignant Carcinoid Syndrome|Renal Cell Carcinoma|Skin Cancer|Pancreatic Cancer|Gastrointestinal Cancer|Insulinoma|Gastrinoma|Non-Small-Cell Lung Cancer|Thyroid Cancer|Oncology Hematological Unspecified|Hypertension

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
ALIMTA

P1

Completed

Hypertension

2016-08-04

CPTK787

P2

Completed

Carcinoid Tumor|Neuroendocrine Tumors

2010-11-01

NU 05C4

P2

Completed

Brain Stem Cancer|Sarcoma|Meningioma

2010-11-01

PTK/RAD

P1

Completed

Kidney Cancer

2010-08-01

Recent News Events

Date

Type

Title

03/01/2024

PubMed

 Traditional Chinese Medicine formula, Sanwujiao granule, attenuates ischemic stroke by promoting angiogenesis through early administration.

02/01/2024

PubMed

 Analysis of vascular disruption in zebrafish embryos as an endpoint to predict developmental toxicity.

12/05/2023

PubMed

 Hyperipersions A-C, three new acylphloroglucinols from the branches and leaves of Hypericum perforatum L. with antiangiogenic activities.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions